Ravi Anandakrishnan, MD
Hematology-Oncology · Baltimore, MDNPI 1912972522
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,089 of the $3,497 with a category attached, or 88.3%. It is spread thinly across 31 manufacturers, the largest accounting for just 7.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,545 and has fallen 84.7% since, to $236 in 2023.
Across 155 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$269
- E.r. Squibb & Sons, L.L.C.$251
- Merck$239
- GSK$224
- Pharmacyclics LLC, An Abbvie Company$214
- Amgen$204
- plus $2K from 25 others
What the payments were for
- Consulting fees$1003%
- Food & beverage$3,08988%
- Education$3089%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $269 |
| E.r. Squibb & Sons, L.L.C. | 12 | $251 |
| Merck | 14 | $239 |
| GSK | 9 | $224 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $214 |
| Amgen(2 entities) | 11 | $204 |
| Celltrion USA Inc. | 2 | $202 |
| Johnson & Johnson(2 entities) | 6 | $157 |
| AstraZeneca | 8 | $155 |
| Eisai Inc. | 7 | $148 |
| Sanofi | 7 | $147 |
| Seagen Inc. | 3 | $135 |
| Lilly USA, LLC | 6 | $125 |
| Genentech USA, Inc. | 7 | $116 |
| Bristol Myers Squibb | 6 | $114 |
| Pfizer | 8 | $112 |
| Comsort, Inc | 1 | $100 |
| Exelixis Inc. | 4 | $99 |
| Boehringer Ingelheim | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $66 |
| Astellas Pharma US Inc | 3 | $61 |
| Incyte Corporation | 2 | $46 |
| Rigel Pharmaceuticals, Inc. | 2 | $42 |
| Genentech, Inc. | 1 | $40 |
| EMD Serono, Inc. | 2 | $38 |
| Acceleron Pharma, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Global Blood Therapeutics, Inc. | 1 | $16 |
| Gilead | 1 | $14 |
| Organon | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 25 | $287,073 |
| GilotrifAfatinib Dimaleate | 12 | $140,124 |
| EliquisApixaban | 37 | $47,769 |
| Dexamethasone | 20 | $592 |
| Anastrozole | 22 | $337 |
| Oxycodone Hcl | 15 | $259 |
| Hydroxyurea | 13 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $114 | $287,07325 claims |
| Boehringer IngelheimGilotrif | $93 | $140,12412 claims |
| PfizerEliquis | $112 | $47,76937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Baltimore
- May Tun SaungBaltimore$0
- Katherine RappazzoBaltimore$0
- Moonjung JungBaltimore$0
- Emily FayBaltimore$0
- Samantha VogtBaltimore$0
- Xiaoyan WangGreenbelt$4K
- Philip KonitsFinksburg$2K
- Cheryl AylesworthWheaton$2K
- Vernon MackieBethesda$2K
- Carolyn HendricksBethesda$641
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.